FDA approves new drug for chronic lymphocytic leukemia

On April 11, the U.S. the Food and Drug Administration (FDA) approved Venclexta (venetoclax) for the treatment of patients with chronic lymphocytic leukemia who have the chromosomal abnormality 17p deletion and who have been treated with at least one prior therapy. Read more


Please enter your comment!
Please enter your name here